schizoidman@lemmy.zip

schizoidman@lemmy.zip

schizoidman@lemmy.zip to

Global News@lemmy.zipEnglish · 5 days ago

AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical

www.reuters.com

AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical

www.reuters.com

schizoidman@lemmy.zip to

Global News@lemmy.zipEnglish · 5 days ago

reuters.com

www.reuters.com

cross-posted from : https://lemmy.zip/post/67889723

You must log in or # to comment.

Chat

Global News@lemmy.zip

globalnews@lemmy.zip

Create a post

You are not logged in. However you can subscribe from another Fediverse account, for example Lemmy or Mastodon. To do this, paste the following into the search field of your instance: !globalnews@lemmy.zip

What is global news?

Something that happened or was uncovered recently anywhere in the world. It doesn’t have to have global implications. Just has to be informative in some way.

Post guidelines

Title format

Post title should mirror the news source title. If you don’t like the title of article, look for an alternative source instead of editorializing it.

URL format

Post URL should be the original link to the article (even if paywalled) and archived copies left in the body. It allows avoiding duplicate posts when cross-posting.

[Opinion] prefix

Opinion (op-ed) articles must use [Opinion] prefix before the title. Opinion articles refer to articles that their publisher doesn’t explictly endorse.

Country prefix

Country prefix can be added to the title with a separator (|, :, etc.) if the news is from a local publisher who doesn’t clearly mention the country.

Rules

This community is moderated in accordance with the principles outlined in Article 19 of the Universal Declaration of Human Rights, which emphasizes the right to freedom of opinion and expression. In addition to this foundational principle, we have some additional rules to ensure a respectful and constructive environment for all users.

1. English only

Title and associated content has to be in English.

2. No social media posts

Avoid all social media posts. Try searching for a source that has a written article or transcription on the subject.

3. Respectful communication

All communication has to be respectful of differing opinions, viewpoints, and experiences.

4. Inclusivity

Everyone is welcome here regardless of age, body size, visible or invisible disability, ethnicity, sex characteristics, gender identity and expression, education, socio-economic status, nationality, personal appearance, race, caste, color, religion, or sexual identity and orientation. Any kind of discrimination is will not be tolerated.

5. Ad hominem attacks

Any kind of personal attacks are expressly forbidden. If you can’t argue your position without attacking a person’s character, you already lost the argument.

6. Off-topic tangents

Stay on topic. Keep it relevant.

7. Instance rules may apply

If something is not covered by community rules, but are against lemmy.zip instance rules, they will be enforced.

Companion communities

!legalnews@lemmy.zip - International and local legal news.
!technology@lemmy.zip - News community around technology, social media platforms, information technology and governmental policy surrounding it.
!interestingshare@lemmy.zip - Fascinating articles, captivating images, satisfying videos, interesting projects, stunning research and more.
!europe@lemmy.dbzer0.com - News and information about Europe.
!usa@midwest.social - News and information about United States of America.

Icon generated via LLM model | Banner attribution

If someone is interested in moderating this community, message @brikox@lemmy.zip.

Visibility: Public

This community can be federated to other instances and be posted/commented in by their users.

621 users / day
1.4K users / week
2.86K users / month
7.45K users / 6 months
11 local subscribers
6.75K subscribers
16.5K Posts
36.9K Comments
Modlog

mods:
BrikoX@lemmy.zip